Follow BPI on Twitter
Full Text (PDF)
In September the FDA approved Stelara ustekinumab, a monoclonal antibody (MAb) for adults with moderate to severe psoriasis. This biologic treats psoriasis by blocking the action of two proteins that contribute to the overproduction of skin cells and inflammation.
The approval came with strings attached, however. The drug maker Centocor Ortho Biotech Inc. (a subsidiary of Johnson & Johnson) will be required to complete a risk evaluation and mitigation strategy (REMS) that includes a communication plan targeted to healthcare providers as well as a medication guide for patients.
Facility Design Strategies for Single-Use Technologies
Please join us for a free webinar addressing strategies for facility design in biopharmaceutical manufacturing:
Wednesday, 29 February 2012
8:00 AM and 1:00 PM EST
Presented by:
Ingrid Long, MSc
Research Engineer
GE Healthcare Life Sciences
During the webinar, Ms. Long will discuss the impact of different strategies for facility design, with a focus on the following topics:
* Replacement of traditional equipment with the single-use equivalent
* Biopharmaceutical manufacturing in a single room
* Benefits of facility design with respect to cost, risk, and flexibility